177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response

被引：0
|
作者：
Kambiz Rahbar
Martin Bögemann
Hojjat Ahmadzadehfar
机构：
[1] University Hospital of Muenster,Department of Nuclear Medicine
[2] University Hospital of Muenster,Department of Urology
[3] University Hospital of Bonn,Department of Nuclear Medicine
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2017年 / 44卷
关键词：
PSMA-617; Radioligand therapy; mCRPC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：166 / 167
页数：1
相关论文
共 50 条
  • [21] Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
    Khreish, Fadi
    Kochems, Niklas
    Rosar, Florian
    Sabet, Amir
    Ries, Martin
    Maus, Stephan
    Saar, Matthias
    Bartholomae, Mark
    Ezziddin, Samer
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (01) : 103 - 112
  • [22] Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC A Proof-of-Principle Application
    Bal, Chandrasekhar
    Yadav, Madhav Prasad
    Ballal, Sanjana
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (08) : E386 - E387
  • [23] Cost Utility Analysis of 177Lu-PSMA-617 Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC) in Germany
    Stargardt, T.
    Brinkmann, C.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S827 - S827
  • [24] 177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy
    Clements, Sarah
    Tempesta, Daniel
    Jacene, Heather
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2022, 50 (03) : 213 - 214
  • [25] Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Ferdinandus, Justin
    Eppard, Elisabeth
    Kuerpig, Stefan
    Gaertner, Florian
    Fimmers, Rolf
    Hauser, Stefan
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [26] Dual PSMA/FDG PET/CT for assessing eligibility and predicting response in mCRPC patients undergoing 177Lu-PSMA-617 radioligand therapy: A post-VISION analysis
    Babu, Anushna S.
    Tripathi, Madhavi
    Yadav, Madhav
    Ballal, Sanjana
    Satapathy, Swayamjeet
    Bal, Chandrasekhar
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [27] Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Ferdinandus, J.
    Eppard, E.
    Kuerpig, S.
    Gaertner, F.
    Fimmers, R.
    Yordanova, A.
    Hauser, S.
    Essler, M.
    Feldmann, G.
    Ahmadzadehfar, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S212 - S213
  • [28] 177Lu-PSMA-617: Brazilian Experience
    Villas Boas, Cristian Wieczorek
    Silva, Jefferson de Jesus
    Benedetto, Raquel
    Mengatti, Jair
    De Araujo, Elaine Bortoleti
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [29] Feasibility of 177Lu-PSMA-617 radioligand therapy in a patient with recurrent high-grade glioma
    Holzgreve, A.
    Delker, A.
    Wenter, V.
    Zacherl, M. J.
    Thon, N.
    Harter, P.
    Brendel, M.
    Unterrainer, L. M.
    Niyazi, M.
    Bartenstein, P.
    von Baumgarten, L.
    Albert, N. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S217 - S217
  • [30] Radioligand Therapy with 177Lu-PSMA-617 in Patients with Diffuse Bone Marrow Involvement: Safety and Efficacy
    Groner, Daniel
    Ngoc, Christina Nguyen
    Davis, Karen
    Happel, Christian
    Baumgarten, Justus
    Banek, Severine
    Mandel, Philipp
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
12345